Helomics Awarded Unique CPT Codes - (Category I MAAA) for ChemoFx® By American Medical Association

New CPTs are a significant milestone for ChemoFx® - Chemo Treatment Selection Marker and Comprehensive Tumor Profiling with PCAP™, (A key to Elucidation of Individualized Patient Tumor Biology)

PITTSBURGH--()--Helomics™ Corporation, a privately-held comprehensive personalized healthcare company that provides comprehensive tumor profiling utilizing proprietary live cell and fixed cell products as well as other lab services, announced today that the American Medical Association’s CPT® Editorial Board has awarded Helomics’ flagship live cell assay, ChemoFx®, its own unique CPT codes. To receive a unique CPT code, a product must satisfy a stringent set of criteria and undergo a number of reviews. In the future, these codes will allow for an accurate, unique description of this key tool used during the treatment decision making process managed by physicians. The codes are 81535 & 81536.

About ChemoFx®

ChemoFx® is a treatment selection marker for chemotherapies. As part of the PCAP™ System, ChemoFx is an assay that quantifies an individual gynecologic cancer patient's probable tumor response to various chemotherapeutic and biologic agents—providing both sensitivity and resistance information. ChemoFx is intended to be utilized in conjunction with treatment guidelines, heuristics and pathways to optimize the decision making process and allow physicians and care-giver teams the opportunity to favorably impact the standard of care.

By testing multiple chemotherapies on a patient's cancer cells before treating the cancer patient, ChemoFx helps determine the chemotherapies that are more likely to be effective on the tumor, and helps guide the physician away from therapies that are more likely to be ineffective - giving patients a powerful advantage in the fight against gynecologic cancer.

A recent study demonstrates improvement in progression-free and overall survival for both platinum-sensitive and platinum-resistant recurrent ovarian cancer when patients are treated with agents identified as sensitive by ChemoFx.

• ChemoFx results were associated with a 14 month (65%) increase in mean overall survival and a 50% improvement in progression-free survival

• Both overall and progression-free survival differences persisted after controlling for other factors through multivariate analysis (HR=0.66, p=0.02)

• The effect was similar in both platinum-sensitive and platinum-resistant tumors

About Precision Cellular Analytical Platform (PCAP™)

PCAP™ is Helomics’ proprietary live tumor cell platform for personalized comprehensive tumor profiling. Physicians and researchers send tumor specimens to Helomics who proprietarily grow the patient’s tumors and continuously analyze the proliferative cell cycling of the tumor on a personalized basis. After complete tumor growth, the specimens are then treated with therapeutic drugs to assess the degree of response sensitivities to particular modalities. The PCAP platform has been meticulously refined for over 15 years and is currently in its 3rd generation of tumor biology elucidation.

About Helomics Corporation, Inc.

Helomics is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a comprehensive personalized tumor profile utilizing a proprietary set of laboratory platforms that leverage both live and fixed cellular analysis to allow physicians to personally characterize malignant tumors. Helomics’ novel molecular and cellular markers and bioinformatics services are designed to support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer.

Helomics is headquartered in Pittsburgh, Pennsylvania where the company maintains two CLIA-certified laboratories. For more information please visit: www.helomics.com.

Forward-Looking Statements

This release may contain forward-looking statements that involve risks and uncertainties. Market conditions and important factors that could cause actual results to differ materially from those communicated in any forward-looking statements information disclosed in presentations, conference calls or other public venues. We do not intend to update any forward-looking statements after the date of this press release.

Contacts

Tiberend Strategic Advisors, Inc. for Helomics
Investors
Joshua Drumm, Ph.D., 212-375-2664
jdrumm@tiberend.com
or
Media
Claire Sojda, 212-375-2686
csojda@tiberend.com

Contacts

Tiberend Strategic Advisors, Inc. for Helomics
Investors
Joshua Drumm, Ph.D., 212-375-2664
jdrumm@tiberend.com
or
Media
Claire Sojda, 212-375-2686
csojda@tiberend.com